Journal

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)

Read time: 1 mins

Published:31st Jul 2017

Author: Blauvelt A, Papp KA, Lebwohl MG, Green LJ, Hsu S, Bhatt V et al.

Source: Journal of the American Academy of Dermatology

Availability: Free full text

Ref.:J Am Acad Dermatol. 2017 Aug;77(2):372-374.

DOI:10.1016/j.jaad.2017.03.026

Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3

Brodalumab, a human monoclonal antibody that binds to interleukin (IL)-17RA (receptor subunit utilized by pro-inflammatory cytokines IL-17A, IL-17F, and IL-17A/F), has been shown at doses of 210 mg every 2 weeks to be superior to ustekinumab and placebo in treating moderate-to-severe plaque psoriasis in 2 large phase 3 studies: AMAGINE-2 and AMAGINE-3.^{1, 2} Time to achieve significant improvements in psoriasis disease severity is an important aspect of patient treatment and education. Our objective was to evaluate the speed of action of brodalumab with the use of data from AMAGINE-2 and AMAGINE-3.

Access full article